Thrombotic microangiopathy in cancer

Area of Science:

• Hematology
• Oncology
• Nephrology

Background:

• Thrombotic microangiopathy (TMA) is a critical condition characterized by thrombocytopenia, microangiopathic hemolytic anemia (MAHA), and organ damage.
• TMA encompasses disorders like thrombotic thrombocytopenic purpura (TTP), atypical hemolytic uremic syndrome (aHUS), and Shiga toxin-related HUS (STEC-HUS).
• Cancer and its treatments, including chemotherapy and hematopoietic stem cell transplantation (HSCT), are increasingly recognized as triggers for TMA, particularly aHUS-like syndromes.

Purpose of the Study:

• To review the pathophysiology of TMA in the context of cancer.
• To discuss chemotherapy-associated HUS and HSCT-related TMA.
• To highlight emerging therapeutic interventions for TMA in these patient populations.

Main Methods:

• Literature review of existing studies on TMA in cancer patients.
• Analysis of the mechanisms linking cancer, chemotherapy, and HSCT to TMA.
• Synthesis of current and novel treatment strategies for TMA.

Main Results:

• Cancer is associated with both macro and microvascular thrombosis.
• Chemotherapy and HSCT can precipitate atypical hemolytic uremic syndrome (aHUS)-like conditions.
• Understanding the pathophysiology is key to developing targeted therapies.

Conclusions:

• TMA presents a significant challenge in oncology and transplant settings.
• Further research into the specific mechanisms of TMA in cancer is warranted.
• New therapeutic approaches offer hope for improved management of TMA.